Characteristics

All (N = 20)

Time to start treatment (months)

p-value

No.

(%)

Mean

±SD

Median

(Range)

Age

≤60 years

12

(60%)

11.16

±3.37

12.50

(4 - 14)

0.026•

>60 years

8

(40%)

7.75

±3.28

7.50

(2 - 12)

Sex

Male

14

(70%)

9.85

±4.14

11.5

(2 - 14)

0.919*

Female

6

(30%)

9.66

±2.58

9

(7 - 14)

Hepatomegally

Absent

11

(55%)

9.63

±3.58

11

(4 - 14)

0.833*

Present

9

(45%)

10

±4

10

(2 - 14)

Lymphadenopathy

Absent

7

(35%)

10.14

±4.18

11

(2 - 14)

0.769*

Present

13

(65%)

9.61

±3.54

8

(4 - 14)

Spleenomegally

Absent

11

(55%)

10.45

±3.38

12

(4 - 14)

0.394*

Present

9

(45%)

9

±4.06

10

(2 - 14)

WBCs

<100 × 10³/mm³

15

(75%)

10.46

±3.52

11

(4 - 14)

0.157^•

≥100 × 10³/mm³

5

(25%)

7.80

±3.76

8

(2 - 12)

Absolute lymphocytes

<30 × 10³/mm³

13

(65%)

11.15

±3.23

12

(4 - 14)

0.018•

≥30 × 10³/mm³

7

(35%)

7.28

±3.25

7

(2 - 12)

Lymphocytic doubling time

<12 months

14

(70%)

10.14

±3.63

10.50

(2 - 14)

0.539*

>12 months

6

(30%)

9

±4

9.50

(4 - 14)

Cytogenetic analysis

Normal

12

(60%)

9.58

±3.50

9.50

(4 - 14)

0.946‡

del 13

3

(15%)

10

±3.46

8

(8 - 14)

del 11

1

(5%)

11

Trisomy 12

4

(20%)

10

±5.65

12

(2 - 14)

CD38

<30%

17

(85%)

10.17

±3.35

11

(2 - 14)

0.288*

>30%

3

(15%)

7.66

±5.50

5

(4 - 14)

MCL-1

<25%

9

(45%)

10.66

±4.03

12

(2 - 14)

0.233•

>25%

11

(55%)

9.09

±3.38

8

(4 - 14)

BCL-2

<10%

7

(35%)

11.71

±2.75

13

(8 - 14)

0.077•

>10%

13

(65%)

8.76

±3.78

8

(2 - 14)

ZAB-70

<20%

6

(30%)

8.50

±3.88

8

(4 - 14)

0.314*

>20%

14

(70%)

10.35

±3.58

11

(2 - 14)

BCL-2/Bax ratio

≤1.6

17

(85%)

10.35

±3.69

11

(2 - 14)

0.077•

>1.6

3

(15%)

6.66

±1.52

7

(5 - 8)